Literature DB >> 25317609

Evaluation of the cisplatin nephrotoxicity using the urinary neutrophil gelatinase-associated lipocalin (NGAL) in patients with head and neck cancer.

Luis Alberto Batista Peres1, Ademar Dantas da Cunha1, Rosangela Aparecida Botinha Assumpção2, Alex Schäfer3, Aline Liene da Silva3, Arianne Ditzel Gaspar3, Deborah Francisca Scarpari3, Julia Barazetti Ferrari Alves3, Rodolfo Girelli Neto3, Thaís Figueiredo Teodoro de Oliveira3.   

Abstract

INTRODUCTION: Acute kidney injury (AKI) in patients receiving cisplatin is common, therefore the evaluation of renal function in patients on use of nephrotoxic drugs is fundamental.
OBJECTIVE: To evaluate the incidence of AKI and the role of lipocalin associated to neutrophil gelatinase (NGAL) in the monitoring of renal function in patients with head and neck cancer (HNC) who received cisplatin.
METHODS: We prospectively studied 50 patients with HNC treated with three sessions of cisplatin. Blood and urine were collected 24 hours before cisplatin, 24 hours after infusion, 48 hours after each application and 35 days after the end of treatment (urine NGAL, C-reactive protein, creatinine, glomerular filtration rate, plasma lactate dehydrogenase and magnesium).
RESULTS: AKI was observed in 78% of patients. There was increase in creatinine, and decrease in GFR after each cycle of cisplatin, and increased urine NGAL. Positive association was observed between the levels of NGAL, creatinine and C-reactive protein. It was observed an increase in creatinine, NGAL, C-reactive protein and decreased GFR in AKI patients compared to patients without AKI.
CONCLUSION: AKI was noted in 78% of patients with HNC treated with cisplatin and showed the correlation of NGAL with creatinine and GFR in demonstrating renal injury. NGAL levels may be elevated compared to baseline levels, even before the use of cisplatin.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25317609     DOI: 10.5935/0101-2800.20140041

Source DB:  PubMed          Journal:  J Bras Nefrol        ISSN: 0101-2800


  10 in total

1.  Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients.

Authors:  Haruka Shinke; Satohiro Masuda; Yousuke Togashi; Yasuaki Ikemi; Aiko Ozawa; Tomoko Sato; Young Hak Kim; Michiaki Mishima; Takaharu Ichimura; Joseph V Bonventre; Kazuo Matsubara
Journal:  Cancer Chemother Pharmacol       Date:  2015-09-25       Impact factor: 3.333

2.  Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity.

Authors:  Melanie S Joy; Lauren M Aleksunes; Blessy George; Xia Wen; Nickie Mercke; Madeleine Gomez; Cindy O'Bryant; Daniel W Bowles; Yichun Hu; Susan L Hogan
Journal:  Clin Pharmacol Ther       Date:  2017-02-14       Impact factor: 6.875

Review 3.  Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Authors:  Shigeo Horie; Mototsugu Oya; Masaomi Nangaku; Yoshinari Yasuda; Yasuhiro Komatsu; Motoko Yanagita; Yuko Kitagawa; Hiroyuki Kuwano; Hiroyuki Nishiyama; Chikashi Ishioka; Hiromasa Takaishi; Hideki Shimodaira; Akira Mogi; Yuichi Ando; Koji Matsumoto; Daisuke Kadowaki; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2018-02       Impact factor: 2.801

4.  Urine biomarkers of acute kidney injury in noncritically ill, hospitalized children treated with chemotherapy.

Authors:  Maya Sterling; Zubaida Al-Ismaili; Kelly R McMahon; Melissa Piccioni; Michael Pizzi; Theresa Mottes; Larry C Lands; Sharon Abish; Adam J Fleming; Michael R Bennett; Ana Palijan; Prasad Devarajan; Stuart L Goldstein; Maureen M O'Brien; Michael Zappitelli
Journal:  Pediatr Blood Cancer       Date:  2017-04-18       Impact factor: 3.167

Review 5.  Clinical Relevance and Predictive Value of Damage Biomarkers of Drug-Induced Kidney Injury.

Authors:  Sandra L Kane-Gill; Pamela L Smithburger; Kianoush Kashani; John A Kellum; Erin Frazee
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

6.  Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trial.

Authors:  Behrooz Heydari; Hossein Khalili; Mohammad-Taghi Beigmohammadi; Alireza Abdollahi; Iman Karimzadeh
Journal:  J Res Med Sci       Date:  2017-03-15       Impact factor: 1.852

7.  Prediction Value of Serum NGAL in the Diagnosis and Prognosis of Experimental Acute and Chronic Kidney Injuries.

Authors:  Weida Wang; Zhaojun Li; Yuanyuan Chen; Haijie Wu; Sen Zhang; Xiaoguang Chen
Journal:  Biomolecules       Date:  2020-06-30

Review 8.  Molecular Mechanisms and Biomarkers Associated with Chemotherapy-Induced AKI.

Authors:  Letizia De Chiara; Gianmarco Lugli; Gianluca Villa; Valentina Raglianti; Faeq Husain-Syed; Fiammetta Ravaglia; Paola Romagnani; Elena Lazzeri
Journal:  Int J Mol Sci       Date:  2022-02-27       Impact factor: 5.923

9.  Predicting Acute Renal Injury in Cancer Patients Receiving Cisplatin Using Urinary Neutrophil Gelatinase-Associated Lipocalin and Cystatin C.

Authors:  Michael J Jelinek; Sang Mee Lee; Alicia Wyche Okpareke; Claudia Wing; Jay L Koyner; Patrick T Murray; Walter M Stadler; Peter H O' Donnell
Journal:  Clin Transl Sci       Date:  2018-04-24       Impact factor: 4.689

10.  Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial.

Authors:  Eman Ghonaim; Sahar El-Haggar; Suzy Gohar
Journal:  Med Oncol       Date:  2021-08-06       Impact factor: 3.064

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.